Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 1/2008

01-02-2008 | Original Article

Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms

Authors: Amir Ghorbanihaghjo, Pegah Veisi, Hassan Argani, Mohammad Aghaeishahsavari, Masood Noroozianavval, Nadereh Rashtchizadeh, Mehran Mesgari, Javid Safa, Hosain Babaei

Published in: Clinical and Experimental Nephrology | Issue 1/2008

Login to get access

Abstract

Background

In this study the effect of losartan and enalapril on the reduction of DNA damage was evaluated in regard to renin-angiotensin system (RAS) polymorphisms.

Methods

After determination of genotypes of RAS polymorphism by PCR, 64 renal transplant recipients were randomly allocated to one of four groups: the first and second groups were treated with E (E+: 10 mg/day) and L (L+: 50 mg/day) alone, respectively. The third group received E+L (E+L+: 10 + 50 mg/day), and the forth group received no medication (E−L−). The subjects were followed for 8 weeks. After a 2-week washout period, the E group changed to L and vice versa as a cross-over design. They were followed for another 8 weeks. Before and after treatment, we checked 8-OHdG and malondialdehyde (MDA) as biomarkers of DNA damage and lipid peroxidation, respectively.

Results

8-OHdG levels were significantly decreased after treatment in the E+L+ and L+ groups (P < 0.001, P = 0.001, respectively). Only the TT genotype of AGT had the most antioxidative role regarding the treatment (P = 0.01). We found a remarkable correlation between MDA and DNA damage levels before and after intervention (r = 0.48, P < 0.001; r = 0.35, P = 0.006).

Conclusion

The protective effects of L+ and E+L+ on DNA breaks are surprising regarding the RAS polymorphisms.
Literature
1.
Schriner SE, Ogburn CE, Smith AC, Newcomb TG, Ladiges WC, Dolle ME, et al. Levels of dna damage are unaltered in mice overexpressing human catalase in nuclei. Free Radic Bio Med. 2000;29:664–73.CrossRef
2.
Grune T, Davies KJ. Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells. Biofactors. 1997;6:165–72.CrossRefPubMed
3.
Halliwell B. Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am J Clin Nutr. 2000;72:1082–7.CrossRefPubMed
4.
de Groot H. Reactive oxygen species in tissue injury. Hepatogastroenterology. 1994;41:328–32.PubMed
5.
6.
Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J. 1990;4:2587–97.CrossRefPubMed
7.
Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2′-deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci USA. 1990;87:4533–7.CrossRefPubMed
8.
Mei S, Yao Q, Wu C, Xu G. Determination of urinary 8-hydroxy-2′-deoxyguanosine by two approaches-capillary electrophoresis GC/MS: an assay for in vivo oxidative DNA damage in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:83–7.CrossRefPubMed
9.
Kuchino Y, Mori F, Kasai H, Inoue H, Iwai S, Miura K, et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature. 1987;327:77–9.CrossRefPubMed
10.
Shi M, Takeshita H, Komatsu M, Xu B, Aoyama K, Takeuchi T. Generation of 8-hydroxydeoxyguanosine from DNA using rat liver homogenates. Cancer Sci. 2005;96:13–8.CrossRefPubMed
11.
Arnett SD, Osbourn DM, Moore KD, Vandaveer SS, Lunte CE. Determination of 8-oxoguanine and 8-hydroxy-2′-deoxyguanosine in the rat cerebral cortex using microdialysis sampling and capillary electrophoresis with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:16–25.CrossRefPubMedPubMedCentral
12.
Miwa M, Matsumaru H, Akimoto Y, Naito S, Ochi H. Quantitative determination of urinary 8-hydroxy-2′-deoxyguanosine level in healthy Japanese volunteers. Biofactors. 2004;22:249–53.CrossRefPubMed
13.
Shigenaga MK, Ames BN. Assays for 8-hydroxy-2′-deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med. 1991;10:211–6.CrossRefPubMed
14.
Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13:2241–7.CrossRefPubMed
15.
Bogdanov MB, Beal MF, McCabe DR, Griffin RM, Matson WR. A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods. Free Radic Biol Med. 1999;27:647–66.CrossRefPubMed
16.
Vural A, Yilmaz MI, Caglar K, Aydin A, Sonmez A, Eyileten T, et al. Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol. 2005;25:250–5.CrossRefPubMed
17.
Krivosikova Z, Dusinska M, Spustova V, Sebekova K, Blazicek P, Heidland A, et al. DNA damage of lymphocytes in experimental chronic renal failure: beneficial effects of losartan. Kidney Int Suppl. 2001;78:212–5.CrossRef
18.
Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease, incidence, clinical correlated, and outcomes: a 20-year clinical experience. Am J Kidney Dis. 1994;24:622–9.CrossRefPubMed
19.
Akcay A, Ozdemir FN, Atac FB, Sezer S, Verdi H, Arat Z, et al. Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response. Transplant Proc. 2004;36:35–7.CrossRefPubMed
20.
Yavuz D, Koc M, Toprak A, Akpinar I, Velioglu A, Deyneli O, et al. Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst. 2003;4:197–203.CrossRefPubMed
21.
Pechter U, Aunapuu M, Riispere Z, Vihalemm T, Kullissaar T, Zilmer K, et al. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Nephron Exp Nephrol. 2004;97:33–7.CrossRef
22.
Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005;18:1496–502.CrossRefPubMed
23.
Khaper N, Singal PK. Modulation of oxidative stress by a selective inhibition of angiotensin II type1 receptors in MI rats. J Am Coll Cardiol. 2001;37:1461–6.CrossRefPubMed
24.
Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003;284:863–9.CrossRef
25.
Bartosz M, Kedziora J, Bartosz G. Antioxidant and prooxidant properties of captopril and enalapril. Free Radic Bio Med. 1997;23:729–35.CrossRef
26.
Schupp N, Schinzel R, Heidland A, Stopper H. Genotoxicity of advanced glycation end products: involvement of oxidative stress and of angiotensin II type 1 receptors. Ann N Y Acad Sci. 2005;1043:685–95.CrossRefPubMed
27.
Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol. 2002;13:1100–8.PubMed
28.
Frishberg Y, Becker-Cohen R, Halle D, Feigin E, Eisenstein B, Halevy R. Genetic polymorphisms of the renin-angiotensin system and the outcome of focal segmental glomerulosclerosis in children. Kidney Int. 1998;54:1843–9.CrossRefPubMed
29.
Ohno T, Kawazu S, Tomono S. Association analyses of the polymorphisms of angiotensin-converting enzyme and angiotensinogen genes with diabetic nephropathy in Japanese non-insulin-dependent diabetics. Metabolism. 1996;45:218–22.CrossRefPubMed
30.
Toyokuni S, Tanaka T, Hattori Y, Nishiyama Y, Yoshida A, Uchida K, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest. 1997;76:365–74.PubMed
31.
Yagi K. Lipid peroxides in hepatic, gastrointestinal, and pancreatic diseases. Adv Exp Med Biol. 1994;366:165–9.CrossRefPubMed
32.
Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 1998;53:1748–54.CrossRefPubMed
33.
34.
Verbeelen DL, De Craemer D, Peeters P, Vanden Houte K, Van den Branden C. Enalapril increases antioxidant enzyme activity in renal cortical tissue of five-sixths-nephrectomized rats. Nephron. 1998;80:214–9.CrossRefPubMed
35.
36.
Vamvakas S, Bahner U, Becker P, Steinle A, Gotz R, Heidland A. Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc. 1996;28:3468–73.PubMed
37.
Halliwell B. Can oxidative DNA damage be used as a biomarker of cancer risk in humans? Problems, resolutions and preliminary results from nutritional supplementation studies. Free Radic Res. 1998;29:469–86.CrossRefPubMed
38.
Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2’-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387:147–63.CrossRefPubMed
39.
Rehman A, Bourne LC, Halliwell B, Rice-Evans CA. Tomato consumption modulates oxidative DNA damage in humans. Biochem Biophys Res commun. 1999;262:828–31.CrossRefPubMed
40.
England T, Beatty E, Rehman A, Nourooz-Zadeh J, Pereira P, O’Reilly J, et al. The steady-state levels of oxidative DNA damage and of lipid peroxidation (F2-isoprostanes) are not correlated in healthy human subjects. Free Radic Res. 2000;32:355–62.CrossRefPubMed
41.
van Zeeland AA, de Groot AJ, Hall J, Donato F. 8-Hydroxydeoxyguanosine in DNA from leukocytes of healthy adults: relationship with cigarette smoking, environmental tobacco smoke, alcohol and coffee consumption. Mutat Res. 1999;439:249–57.CrossRefPubMed
42.
Bianchini F, Elmstahl S, Martinez-Garcia C, van Kappel AL, Douki T, Cadet J, et al. Oxidative DNA damage in human lymphocytes: correlations with plasma levels of alpha-tocopherol and carotenoids. Carcinogenesis. 2000;21:321–4.CrossRefPubMed
43.
Frimat L, Philippe C, Maghakian MN, Jonveaux P, Hurault de Ligny B, et al. Polymorphism of angiotensin converting enzyme, angiotensinogen, and angiotensin II type 1 receptor genes and end-stage renal failure in IgA nephropathy: IGARAS-a study of 274 Men. J Am Soc Nephrol. 2000;11:2062–7.PubMed
44.
Slowinski T, Diehr P, Kleemann P, Fritsche L, Renders L, Budde K, et al. No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant. 2004;19:2846–51.CrossRefPubMed
45.
Nicod J, Richard A, Frey FJ, Ferrari P. Recipient RAS gene variants and renal allograft function. Transplantation. 2002;73:960–5.CrossRefPubMed
46.
Boratynska M, Boratynski J, Klinger M, Szyber P, Pawlowski S, Pupka A, et al. Lipid peroxidation and cytokines in chronic allograft failure: influence of nonimmunological risk factors. Transplant Proc. 2000;32:1384–6.CrossRefPubMed
47.
Perez Fernandez R, Martin Mateo MC, De Vega L, Bustamante Bustamante J, Herrero M, Bustamante Munguira E. Antioxidant enzyme determination and a study of lipid peroxidation in renal transplantation. Ren Fail. 2002;24:353–9.CrossRefPubMed
48.
Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003;482:95–9.CrossRefPubMed
49.
Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–93.CrossRefPubMed
50.
Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res. 2002;90:770–6.CrossRefPubMed
51.
Da Ros R, Assaloni R, Ceriello A. Molecular targets of diabetic vascular complications and potential new drugs. Curr Drug Targets. 2005;6:503–9.CrossRefPubMed
52.
Abdi R, Tran TB, Zee R, Brenner BM, Milford EL. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 2001;72:726–9.CrossRefPubMed
53.
Martinez-Alfaro M, Palma-Tirado L, Sandoval-Zapata F, Carabez-Trejo A. Correlation between formamidopyrimidine DNA glycosylase (Fpg)-sensitive sites determined by a comet assay, increased MDA, and decreased glutathione during long exposure to thinner inhalation. Toxicol Lett 2005 (Epub ahead of print).
54.
Kocyigit A, Kelaes H, Selek S, Guzel S, Celik H, Erel O. Increased DNA damage and oxidative stress in patients with cutaneous leishmaniasis. Mutat Res. 2005;585:71–8.CrossRefPubMed
Metadata
Title
Prevention of DNA damage in renal transplantation by losartan and enalapril: the role of renin-angiotensin system polymorphisms
Authors
Amir Ghorbanihaghjo
Pegah Veisi
Hassan Argani
Mohammad Aghaeishahsavari
Masood Noroozianavval
Nadereh Rashtchizadeh
Mehran Mesgari
Javid Safa
Hosain Babaei
Publication date
01-02-2008
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2008
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-007-0001-x

Other articles of this Issue 1/2008

Clinical and Experimental Nephrology 1/2008 Go to the issue

Original Article

Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan

Review Article

Chronic kidney disease perspectives in Japan and the importance of urinalysis screening

Case Report

Lupus vulgaris with tubercular lymphadenitis and IgA nephropathy

Special Commentary

The Third World Kidney Day: looking back and thinking forward

Original Article

Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans

Review Article

Applications of LDL-apheresis in nephrology
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits